Industry Trends

Latest News


Connection Between People And Artificial Intelligence Technology: © Prostock-studio - stock.adobe.com (AdobeStock 281091481)

In this Q&A with Pharmaceutical Executive®, Andrew Hopkins, founder and CEO of Exscientia, reveals how artificial intelligence (AI) is currently being utilized in the pharma industry, predictions for where AI can be implemented in the future, and what pharma fears most about AI.

Meg Rivers

Here at Pharmaceutical Executive®, we are already planning our editorial calendar for 2024. And each year we go through this process, I consider this a time of reflection to see where the industry has come, what topics always seem to be on the tips of everyone’s tongues, and what should be a topic of focus. Along with artificial intelligence (AI) being top of mind, other topics that come into my inbox again and again relate to diversity, equity, and inclusion (DE&I) and addressing unmet medical needs.

The market for prescription medicines in the United States was subject to major shifts in use across therapeutic areas in 2022, reflecting changes in patient health needs, the development, and availability of novel medicines, and complex market dynamics.

Kevin Fagan: screen shot of video.

Kevin Hagan, president and CEO of the PAN Foundation, spoke to PharmExec about the recent IRA changes to Medicare and how it positively effects patients.

DNA helix colorful genes chromosomes DNA sequence | Image credit:© catalin - stock.adobe.com.

At Pharma USA 2023, Peter Marks, MD, PhD and director of CBER described FDA and public/private partnerships working toward scalable manufacturing approaches to address commercial viability and global access for cell and gene therapies